Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17895970 | 0.90 | KDM4E (0.38) | KDM4EHPGDUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL17893097 | 0.86 | BTK (0.35) | KDM4EHPGDALDH1A1SMN1; SMN2BTK | |
| SCHEMBL30626812 | 0.86 | BTK (0.35) | KDM4EHPGDALDH1A1SMN1; SMN2BTK | |
| SCHEMBL17893399 | 0.82 | HPGD (0.43) | KDM4EHPGDUSP2ALDH1A1BTK | |
| SCHEMBL402325 | 0.82 | HPGD (0.50) | KDM4EHPGDUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL17895129 | 0.81 | KDM4E (0.32) | KDM4EHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL16748916 | 0.80 | HPGD (0.49) | KDM4EHPGDUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL22235969 | 0.80 | HPGD (0.40) | KDM4EHPGDUSP2ALDH1A1BTK | |
| SCHEMBL14647352 | 0.79 | HPGD (0.48) | KDM4EHPGDUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL17893265 | 0.79 | HPGD (0.41) | KDM4EHPGDUSP2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362243-A1 | BIARYLETHER IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3240545-A1 | BIARYLETHER IMIDAZOPYRAZINE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109219-A1 | BIARYLETHER IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362243-A1 | BIARYLETHER IMIDAZOPYRAZINE BTK INHIBITORS | BTK, ABL1, SYK | KDM4E 816/4885HPGD 3884/4885USP2 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.